Advertisement

Genetics of Breast Cancer

Risk Models, Who to Test, and Management Options
Published:October 17, 2022DOI:https://doi.org/10.1016/j.suc.2022.08.016

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Breast cancer facts & figures, Am Cancer Soc, 2021, Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf. Accessed August 4, 2021.

        • Rojas K.
        • Stuckey A.
        Breast cancer epidemiology and risk factors.
        Clin Obstet Gynecol. 2016; 59: 651-672
        • Shiovitz S.
        • Korde L.A.
        Genetics of breast cancer: a topic in evolution.
        Ann Oncol. 2015; 26: 1291-1299
        • Valencia O.M.
        • Samuel S.E.
        • Viscusi R.K.
        • et al.
        The role of genetic testing in patients with breast cancer: a review.
        JAMA Surg. 2017; 152: 589-594
        • Keeney M.G.
        • Couch F.J.
        • Visscher D.W.
        • et al.
        Non-BRCA familial breast cancer: review of reported pathology and molecular findings.
        Pathology. 2017; 49: 363-370
        • Economopoulou P.
        • Dimitriadis G.
        • Psyrri A.
        Beyond BRCA: new hereditary breast cancer susceptibility genes.
        Cancer Treat Rev. 2015; 41: 1-8
      2. Consensus Guideline on Hereditary Genetic Testing for Patients With and Without Breast Cancer.
        (Available at:) (Accessed August/13/2018)
        • Owens D.K.
        • Davidson K.W.
        • Krist A.H.
        • et al.
        Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer.
        JAMA. 2019; 322: 652
        • Rajagopal P.S.
        • Nielsen S.
        • Olopade O.I.
        USPSTF recommendations for BRCA1 and BRCA2 testing in the context of a transformative national cancer control plan.
        JAMA Netw Open. 2019; 2: e1910142
        • Daly M.B.
        • Pal T.
        • Berry M.P.
        • et al.
        Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in oncology.
        J Natl Compr Canc Netw. 2021; 19: 77-102
        • Gilpin C.
        • Carson N.
        • Hunter A.
        A preliminary validation of a family history assessment form to select women at risk for breast or ovarian cancer for referral to a genetics center.
        Clin Genet. 2000; 58: 299-308
        • Cintolo-Gonzalez J.A.
        • Braun D.
        • Blackford A.L.
        • et al.
        Breast cancer risk models: a comprehensive overview of existing models, validation, and clinical applications.
        Breast Cancer Res Treat. 2017; 164: 263-284
        • Gail M.H.
        • Brinton L.A.
        • Byar D.P.
        • et al.
        Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.
        J Natl Cancer Inst. 1989; 81: 1879-1886
        • Matsuno R.K.
        • Costantino J.P.
        • Ziegler R.G.
        • et al.
        Projecting individualized absolute invasive breast cancer risk in asian and pacific islander american women.
        J Natl Cancer Inst. 2011; 103: 951-961
        • Gail M.H.
        • Costantino J.P.
        • Pee D.
        • et al.
        Projecting individualized absolute invasive breast cancer risk in african american women.
        J Natl Cancer Inst. 2007; 99: 1782-1792
        • Banegas M.P.
        • John E.M.
        • Slattery M.L.
        • et al.
        Projecting Individualized absolute invasive breast cancer risk in US hispanic women.
        J Natl Cancer Inst. 2017; 109: djw215
        • Adams-Campbell L.L.
        • Makambi K.H.
        • Palmer J.R.
        • et al.
        Diagnostic accuracy of the Gail model in the Black Women's Health Study.
        Breast J. 2007; 13: 332-336
        • Pankratz V.S.
        • Hartmann L.C.
        • Degnim A.C.
        • et al.
        Assessment of the accuracy of the Gail model in women with atypical hyperplasia.
        J Clin Oncol. 2008; 26: 5374-5379
        • Claus E.B.
        • Risch N.
        • Thompson W.D.
        Genetic analysis of breast cancer in the cancer and steroid hormone study.
        Am J Hum Genet. 1991; 48: 232-242
        • Evans D.G.R.
        • Howell A.
        Breast cancer risk-assessment models.
        Breast Cancer Res. 2007; 9: 213
        • Kim G.
        • Bahl M.
        Assessing risk of breast cancer: a review of risk prediction models.
        J Breast Imaging. 2021; 3: 144-155
        • Claus E.B.
        • Risch N.
        • Thompson W.D.
        Autosomal dominant inheritance of early-onset breast cancer. Implications for risk prediction.
        Cancer. 1994; 73: 643-651
        • Parmigiani G.
        • Berry D.
        • Aguilar O.
        Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.
        Am J Hum Genet. 1998; 62: 145-158
        • Mazzola E.
        • Blackford A.
        • Parmigiani G.
        • et al.
        Recent enhancements to the genetic risk prediction model BRCAPRO.
        Cancer Inform. 2015; 14s2: CIN.S17292
        • Antoniou A.C.
        • Pharoah P.D.
        • McMullan G.
        • et al.
        A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.
        Br J Cancer. 2002; 86: 76-83
        • Antoniou A.C.
        • Pharoah P.P.
        • Smith P.
        • et al.
        The BOADICEA model of genetic susceptibility to breast and ovarian cancer.
        Br J Cancer. 2004; 91: 1580-1590
        • Valero M.G.
        • Zabor E.C.
        • Park A.
        • et al.
        The tyrer–cuzick model inaccurately predicts invasive breast cancer risk in women with LCIS.
        Ann Surg Oncol. 2020; 27: 736-740
        • Boughey J.C.
        • Hartmann L.C.
        • Anderson S.S.
        • et al.
        Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia.
        J Clin Oncol. 2010; 28: 3591-3596
        • Maxwell K.N.
        • Wubbenhorst B.
        • D’Andrea K.
        • et al.
        Prevalence of mutations in a panel of breast cancer susceptibility genes in BRCA1/2-negative patients with early-onset breast cancer.
        Genet Med. 2015; 17: 630-638
      3. Cosgrove J., Genetic services: information on genetic counselor and medical geneticist workforces, In: Office G.A., Online, 2019, United State Government Accountability Office, 1-45, Available at: https://www.gao.gov/assets/gao-20-593.pdf. Accessed January 4, 2022..

        • Plichta J.K.
        • Sebastian M.L.
        • Smith L.A.
        • et al.
        Germline genetic testing: what the breast surgeon needs to know.
        Ann Surg Oncol. 2019; 26: 2184-2190
        • Hall J.M.
        • Lee M.K.
        • Newman B.
        • et al.
        Linkage of early-onset familial breast cancer to chromosome 17q21.
        Science. 1990; 250: 1684-1689
        • Wooster R.
        • Neuhausen S.L.
        • Mangion J.
        • et al.
        Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13.
        Science. 1994; 265: 2088-2090
      4. Supreme Court Decision in Association for Molecular Pathology v. Myriad Genetics, Inc. 2013. Available at: https://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf. Accessed September 11, 2016.

        • Plichta J.K.
        • Griffin M.
        • Thakuria J.
        • et al.
        What's new in genetic testing for cancer susceptibility?.
        Oncology (Williston Park). 2016; 30: 787-799
        • Welsh J.L.
        • Hoskin T.L.
        • Day C.N.
        • et al.
        Clinical decision-making in patients with variant of uncertain significance in BRCA1 or BRCA2 genes.
        Ann Surg Oncol. 2017; 24: 3067-3072
        • Dillon J.
        • Ademuyiwa F.O.
        • Barrett M.
        • et al.
        Disparities in genetic testing for heritable solid-tumor malignancies.
        Surg Oncol Clin N Am. 2022; 31: 109-126
        • Ademuyiwa F.O.
        • Salyer P.
        • Ma Y.
        • et al.
        Assessing the effectiveness of the National Comprehensive Cancer Network genetic testing guidelines in identifying African American breast cancer patients with deleterious genetic mutations.
        Breast Cancer Res Treat. 2019; 178: 151-159
        • Chapman-Davis E.
        • Zhou Z.N.
        • Fields J.C.
        • et al.
        Racial and ethnic disparities in genetic testing at a hereditary breast and ovarian cancer center.
        J Gen Intern Med. 2021; 36: 35-42
        • Forman A.D.
        • Hall M.J.
        Influence of race/ethnicity on genetic counseling and testing for hereditary breast and ovarian cancer.
        Breast J. 2009; 15: S56-S62
        • Reid S.
        • Cadiz S.
        • Pal T.
        Disparities in genetic testing and care among black women with hereditary breast cancer.
        Curr Breast Cancer Rep. 2020; 12: 125-131
        • Cragun D.
        • Weidner A.
        • Lewis C.
        • et al.
        Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
        Cancer. 2017; 123: 2497-2505
        • Ademuyiwa F.O.
        • Salyer P.
        • Tao Y.
        • et al.
        Genetic counseling and testing in african american patients with breast cancer: a nationwide survey of US breast oncologists.
        J Clin Oncol. 2021; 39: 4020-4028
        • Eichmeyer J.N.
        • Zuckerman D.S.
        • Beck T.M.
        • et al.
        The value of a genetic counselor for patient identification.
        J Clin Oncol. 2012; 30: 97
        • Pederson H.J.
        • Hussain N.
        • Noss R.
        • et al.
        Impact of an embedded genetic counselor on breast cancer treatment.
        Breast Cancer Res Treat. 2018; 169: 43-46
      5. Daly M.B., Pal T., Arun B., et al., NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2022. Available online at: https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. Accessed January 4, 2022.

        • Bland K.C.E.
        • Klimberg V.
        • Gradishar W.
        The breast comprehensive management of benign and malignant diseases.
        5th ed. Elsevier, Philadelphia, PA2018
        • Vourtsis A.
        • Berg W.A.
        Breast density implications and supplemental screening.
        Eur Radiol. 2019; 29: 1762-1777
        • Geisel J.
        • Raghu M.
        • Hooley R.
        The role of ultrasound in breast cancer screening: the case for and against ultrasound.
        Semin Ultrasound CT MR. 2018; 39: 25-34
        • Sung J.S.
        • Lebron L.
        • Keating D.
        • et al.
        Performance of dual-energy contrast-enhanced digital mammography for screening women at increased risk of breast cancer.
        Radiology. 2019; 293: 81-88
        • Vreugdenburg T.D.
        • Willis C.D.
        • Mundy L.
        • et al.
        A systematic review of elastography, electrical impedance scanning, and digital infrared thermography for breast cancer screening and diagnosis.
        Breast Cancer Res Treat. 2013; 137: 665-676
        • Yao K.
        • Liederbach E.
        • Tang R.
        • et al.
        Nipple-sparing mastectomy in BRCA1/2 mutation carriers: an interim analysis and review of the literature.
        Ann Surg Oncol. 2015; 22: 370-376
        • Carbine N.E.
        • Lostumbo L.
        • Wallace J.
        • et al.
        Risk-reducing mastectomy for the prevention of primary breast cancer.
        Cochrane Database Syst Rev. 2018; 4: Cd002748
        • Heemskerk-Gerritsen B.A.M.
        • Jager A.
        • Koppert L.B.
        • et al.
        Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.
        Breast Cancer Res Treat. 2019; 177: 723-733
        • Gahm J.
        • Wickman M.
        • Brandberg Y.
        Bilateral prophylactic mastectomy in women with inherited risk of breast cancer--prevalence of pain and discomfort, impact on sexuality, quality of life and feelings of regret two years after surgery.
        Breast. 2010; 19: 462-469
        • Jeffers L.
        • Reid J.
        • Fitzsimons D.
        • et al.
        Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.
        Cochrane Database Syst Rev. 2019; 10: Cd012894
        • van den Broek A.J.
        • Schmidt M.K.
        • van 't Veer L.J.
        • et al.
        Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.
        PLoS One. 2015; 10: e0120189
        • van den Broek A.J.
        • Schmidt M.K.
        • van 't Veer L.J.
        • et al.
        Prognostic impact of breast-conserving therapy versus mastectomy of BRCA1/2 mutation carriers compared with noncarriers in a consecutive series of young breast cancer patients.
        Ann Surg. 2019; 270: 364-372
        • van den Broek A.J.
        • van 't Veer L.J.
        • Hooning M.J.
        • et al.
        Impact of age at primary breast cancer on contralateral breast cancer risk in BRCA1/2 mutation carriers.
        J Clin Oncol. 2016; 34: 409-418
        • Ludwig K.K.
        • Neuner J.
        • Butler A.
        • et al.
        Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
        Am J Surg. 2016; 212: 660-669
        • Tutt A.N.J.
        • Garber J.E.
        • Kaufman B.
        • et al.
        Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer.
        N Engl J Med. 2017; 377: 523-533
        • Robson M.
        • Im S.A.
        • Senkus E.
        • et al.
        Olaparib for metastatic breast cancer in patients with a germline BRCA mutation.
        N Engl J Med. 2017; 377: 523-533
        • Litton J.K.
        • Rugo H.S.
        • Ettl J.
        • et al.
        Talazoparib in patients with advanced breast cancer and a germline BRCA mutation.
        N Engl J Med. 2018; 379: 753-763
        • Gradishar W.J.
        • Moran M.S.
        • Abraham J.
        • et al.
        NCCN Guidelines: Breast Cancer (version 1.2022) 2021;1.
        (Available at:) (Accessed December 13, 2021)
        • Berry D.A.
        • Iversen Jr., E.S.
        • Gudbjartsson D.F.
        • et al.
        BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
        J Clin Oncol. 2002; 20: 2701-2712
        • Antoniou A.C.
        • Cunningham A.P.
        • Peto J.
        • et al.
        The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.
        Br J Cancer. 2008; 98: 1457-1466
      6. https://ems-trials.org/riskevaluator/
        Date accessed: January 4, 2022